文献速递骨质疏松与钙磷/甲状旁腺

健康男性中亲吻素给药对骨代谢的急性效应

Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

研究通过体外实验和随机、安慰剂对照、双盲、两阶段交叉临床研究,在26名健康性腺功能正常男性中评估亲吻素对骨代谢的急性效应。体外亲吻素使人骨髓间充质干细胞碱性磷酸酶升高41.1%(P=.0022),抑制破骨细胞吸收活性达53.4%(P<.0001);体内给药后总骨钙素最大升高20.3%(P=.021),羧化骨钙素最大升高24.3%(P=.014),吸收标志物未升高。

要点

  • 体外亲吻素使人骨髓间充质干细胞碱性磷酸酶升高41.1%(P=.0022),抑制破骨细胞吸收活性达53.4%(P<.0001)。
  • 健康男性急性给药后总骨钙素最大升高20.3%(P=.021),羧化骨钙素最大升高24.3%(P=.014)。
  • 亲吻素急性升高骨形成标志物骨钙素,但不升高吸收标志物,且不依赖下游性类固醇水平。

核心结论

  • 这些数据首次提供人类证据表明亲吻素在体外促进成骨祖细胞的成骨分化并抑制骨吸收。
  • 在健康男性中亲吻素急性升高骨形成标志物骨钙素,但不升高吸收标志物,且不依赖下游性类固醇水平。
  • 亲吻素因此可能在骨质疏松症治疗中具有临床治疗应用。

研究设计与样本

  • 体外研究:用亲吻素处理人成骨细胞与破骨细胞的单培养和共培养。
  • 临床研究:随机、安慰剂对照、双盲、两阶段交叉临床研究,26名男性,研究急性亲吻素给药(90分钟)对人骨代谢的影响,每30分钟采血至+90分钟。
  • 体外研究细胞来自12名男性献血者和8名接受髋关节置换手术的患者。
  • 临床研究纳入26名健康性腺功能正常男性(年龄26.8±5.8岁)。
  • 干预为亲吻素(对照安慰剂)给药,主要结局指标为骨参数和骨转换标志物的变化。

主要发现

  • 体外孵育亲吻素使人骨髓间充质干细胞碱性磷酸酶水平升高41.1%(P=.0022)。
  • 体外亲吻素以剂量依赖方式强烈抑制破骨细胞吸收活性,抑制幅度达53.4%(P<.0001)。
  • 健康男性给予亲吻素后总骨钙素最大升高20.3%(P=.021),羧化骨钙素最大升高24.3%(P=.014)。
  • 亲吻素急性升高骨形成标志物骨钙素,但不升高吸收标志物。

临床怎么用

  • 作者认为亲吻素可能在骨质疏松症治疗中具有临床治疗应用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Osteoporosis results from disturbances in bone formation and resorption. Recent nonhuman data suggest that the reproductive hormone kisspeptin directly stimulates osteoblast differentiation in vitro and thus could have clinical therapeutic potential. However, the effects of kisspeptin on human bone metabolism are currently unknown. OBJECTIVE: To assess the effects of kisspeptin on human bone metabolism in vitro and in vivo. METHODS: In vitro study: of Mono- and cocultures of human osteoblasts and osteoclasts treated with kisspeptin. Clinical study: Randomized, placebo-controlled, double-blind, 2-way crossover clinical study in 26 men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes. Cells for the in vitro study were from 12 male blood donors and 8 patients undergoing hip replacement surgery. Twenty-six healthy eugonadal men (age 26.8 ± 5.8 years) were included in the clinical study. The intervention was Kisspeptin (vs placebo) administration. The main outcome measures were changes in bone parameters and turnover markers. RESULTS: Incubation with kisspeptin in vitro increased alkaline phosphatase levels in human bone marrow mesenchymal stem cells by 41.1% (P = .0022), and robustly inhibited osteoclastic resorptive activity by up to 53.4% (P < .0001), in a dose-dependent manner. Kisspeptin administration to healthy men increased osteoblast activity, as evidenced by a 20.3% maximal increase in total osteocalcin (P = .021) and 24.3% maximal increase in carboxylated osteocalcin levels (P = .014). CONCLUSION: Collectively, these data provide the first human evidence that kisspeptin promotes osteogenic differentiation of osteoblast progenitors and inhibits bone resorption in vitro. Furthermore, kisspeptin acutely increases the bone formation marker osteocalcin but not resorption markers in healthy men, independent of downstream sex steroid levels. Kisspeptin could therefore have clinical therapeutic application in the treatment of osteoporosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Comninos AN, Hansen MS, Courtney A, et al. Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. J Clin Endocrinol Metab. 2022. PMID: 35244717. doi:10.1210/clinem/dgac117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。